September 16, 2020 -- Yufan Biotechnologies and Abound Bio have signed a multiyear agreement to find antibodies to direct chimeric antigen receptor (CAR) T cells against cancer targets.
The three-year deal covers incorporating antibodies to 10 cancer targets into a HPK1- (hematopoietic progenitor kinase 1) inhibited CAR T-cell platform. HPK1 promotes T-cell exhaustion, which is a strategy that can be used to improve CAR T-cell immunotherapy.